Neurochem reports long-term Alzhemed data

Neurochem (TSE:NRM; NRMX) reported 20-month data from an ongoing open-label Phase II extension study of its Alzhemed to treat mild to moderate Alzheimer's disease (AD). In 19 patients, the average ADAS-cog score was 6.2. NRM said comparable historical controls had an average score of 11.9.

The company also reported data from 26 patients who received treatment for 16 weeks, showing an average ADAS-cog score of 5.3. In April, NRM said the first 18 patients who received 16 weeks of treatment had an average ADAS-cog score of 2.7. Historical controls had an average score of 9.6, the company said. ...